Back to Journals » Biologics: Targets and Therapy » Volume 12

Two decades with omalizumab: what we still have to learn

Authors Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E

Received 19 July 2018

Accepted for publication 22 September 2018

Published 26 October 2018 Volume 2018:12 Pages 135—142

DOI https://doi.org/10.2147/BTT.S180846

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Doris Benbrook


Cristoforo Incorvaia,1 Marina Mauro,2 Elena Makri,1 Gualtiero Leo,3 Erminia Ridolo4

1Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy; 2Allergy Department, Sant’Anna Hospital, Como, Italy; 3Pediatric Allergy and Respiratory Pathophysiology Unit, Department of Pediatrics, Vittore Buzzi Children’s Hospital, Milan, Italy; 4Department of Medicine and Surgery, University of Parma, Parma, Italy

Abstract: From its availability for clinical use nearly two decades ago for severe asthma, omalizumab has gained strong evidence of efficacy and safety in the treatment of severe asthma not controlled by standard-of-care therapy. It has been acknowledged by Global Initiative on Asthma guidelines as add-on therapy against severe uncontrolled asthma. Thanks to controlled trials supporting its efficacy, omalizumab has also been licensed for the treatment of chronic spontaneous urticaria. The optimal duration of treatment in either disease has not been established. Despite its high price, omalizumab appears to be cost-effective in severe uncontrolled asthma as well as in chronic urticaria. The literature suggests a wide range of applications for omalizumab in various disorders regardless of allergic or non-allergic pathophysiology.

Keywords: anti-IgE antibody, omalizumab, severe asthma, chronic spontaneous urticaria, efficacy, safety, cost-effectiveness

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]